The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat ... a tablet dosage form of treprostinil, to delay disease ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

However, it has been outperformed in head-to-head trials by Tremfya, as well as Skyrizi, which approached $12 billion in sales last year and is viewed as J&J's fiercest rival in the market.

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

The US Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa, a ...

The FDA has approved Widaplik (telmisartan, amlodipine and indapamide) for the treatment of hypertension, including as initial treatment, to lower blood pressure.

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...

The dosage can vary based on factors including age, sex, and medical history. Vitamin B12 is a water-soluble nutrient that’s required for many crucial processes in your body, such as maintaining ...

"In psoriatic arthritis, joint damage can begin early and progress quickly if left untreated, significantly impacting a patient's ability to move, work and maintain independence," said Philip J. Mease ...